Search results
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
Morningstar· 4 days agoNBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine BiosciencesSuccessful completion ...